Novo Nordisk shares jump after US approves Wegovy for liver disease
Novo Nordisk shares surged on Monday, rising as much as 5% at the open, after U.S. regulators granted accelerated approval for its weight-loss drug Wegovy to treat a progressive liver condition known as MASH.
The approval sparked strong investor interest, boosting confidence in the company’s expanding therapeutic reach, News.Az reports, citing Reuters.
It affects around 5% of adults in the U.S.
That was positive news for the drugmaker, which has seen its value tumble.
Investors wiped $70 billion off its stock three weeks ago after Novo issued a profit warning and named a company veteran as new CEO.
The firm had become Europe's most valuable listed company after the launch of Wegovy four years ago.
But its shares have lost more than two-thirds of their value since June Last year.
Markets are concerned the Danish drugmaker is losing ground in the obesity drug race to copycat drugs and U.S. rival Eli Lilly.
Similar news
